Kaletra approved in Canada.
On March 9, 2001, Health Canada granted permission to Abbott Laboratories for the sale of Kaletra (a combination of protease inhibitors lopinavir and ritonavir), formerly known as ABT-378/r, for the treatment of HIV infection in adults and children six months or older. Kaletra was approved for sale in the U.S. in September 2000.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002170:Canada; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006297:Health Services Accessibility; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir